 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...175176177178179180181182183184185...235236» |
- ||| spartalizumab (PDR001) / Novartis
Trial termination, Combination therapy, Metastases: PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - Jan 11, 2019
P1, N=1, Terminated, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; The study was terminated early due to company decision.
- | Trial termination: Phase ? Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE (clinicaltrials.gov) - Jan 11, 2019
P2, N=79, Terminated, Sponsor: Sun Yat-sen University
Completed --> Terminated; The study was terminated early due to company decision. Recruiting --> Terminated; No patients join
- | oxaliplatin / Generic mfg.
New P2 trial: 2 Versus 6 Hour Oxaliplatin Infusions in Patients with Gastrointestinal Cancers (clinicaltrials.gov) - Jan 11, 2019
P2, N=60, Not yet recruiting, Sponsor: Emory University
- || palupiprant (AN0025) / Eisai, Adlai Nortye
Trial completion date, Trial primary completion date, Combination therapy: PRAER 1: Preoperative Radiotherapy and E7046 in Rectum Cancer (clinicaltrials.gov) - Jan 10, 2019
P1b, N=68, Recruiting, Sponsor: Adlai Nortye Biopharma Co., Ltd.
Recruiting --> Terminated; No patients join Trial completion date: Jan 2019 --> Jun 2020 | Trial primary completion date: Sep 2018 --> Apr 2020
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment change, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Jan 10, 2019
P2/3, N=400, Active, not recruiting, Sponsor: Aslan Pharmaceuticals
Trial completion date: Jan 2019 --> Jun 2020 | Trial primary completion date: Sep 2018 --> Apr 2020 N=40 --> 400
- | New trial: Supportive Oncology Care at Home for Patients With Pancreatic Cancer Receiving Preoperative FOLFIRINOX (clinicaltrials.gov) - Jan 10, 2019
P=N/A, N=60, Not yet recruiting, Sponsor: Massachusetts General Hospital
- ||| gevokizumab (VPM087) / Novartis
New P1 trial, Combination therapy, Metastases: Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers (clinicaltrials.gov) - Jan 10, 2019
P1, N=172, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- | 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Jan 9, 2019
P2, N=50, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
N=40 --> 400 Trial completion date: Nov 2018 --> Mar 2019 | Trial primary completion date: Oct 2017 --> Aug 2018
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: AXEPT: A Phase III Study of 2nd-line XELIRI (clinicaltrials.gov) - Jan 8, 2019
P3, N=650, Completed, Sponsor: Epidemiological and Clinical Research Information Network
Trial completion date: Nov 2018 --> Mar 2019 | Trial primary completion date: Oct 2017 --> Aug 2018 Active, not recruiting --> Completed
- | Imkeldi (imatinib) / Shorla Oncology
Trial completion date, Trial primary completion date, IO biomarker: AALL1631: Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Jan 8, 2019
P3, N=700, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028
- | Avastin (bevacizumab) / Roche
New P1/2 trial: Evaluation of the Efficacy and the Safety of FOLFIRINOX3 Bevacizumab Treatment in Patients With Colorectal Cancer (FOLFIRINOX 3) (clinicaltrials.gov) - Jan 7, 2019
P1/2, N=55, Recruiting, Sponsor: Centre Georges Francois Leclerc
- || AZD0156 / AstraZeneca
Enrollment change, Combination therapy, Monotherapy, PARP Biomarker, Metastases: AToM: Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer (clinicaltrials.gov) - Jan 3, 2019
P1, N=83, Recruiting, Sponsor: AstraZeneca
Trial completion date: Jun 2026 --> Jun 2028 | Trial primary completion date: Jun 2026 --> Jun 2028 N=225 --> 83
- | Vectibix (panitumumab) / Amgen
Enrollment open, Trial primary completion date: PIER: Induction Therapy With Panitumumab + mFOLFOX-6 in Rectal Cancer and Quadruple Wild-type Mutation Before Surgery (clinicaltrials.gov) - Jan 3, 2019
P2, N=47, Recruiting, Sponsor: Grupo Espanol Multidisciplinario del Cancer Digestivo
N=225 --> 83 Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Oct 2020
- | New P2 trial: PET Imaging-guided Chemoradiotherapy in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Jan 3, 2019
P2, N=216, Not yet recruiting, Sponsor: Mian XI
- | New P3 trial: A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer (clinicaltrials.gov) - Dec 27, 2018
P3, N=600, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- | AiTan (rivoceranib) / HLB Bio Group
New P2 trial: Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma (clinicaltrials.gov) - Dec 27, 2018
P2, N=26, Not yet recruiting, Sponsor: Fujian Cancer Hospital
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Trial completion date, Trial primary completion date: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Dec 26, 2018
P2, N=116, Suspended, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2017 --> Oct 2020 Trial completion date: Sep 2019 --> Jun 2021 | Trial primary completion date: Sep 2019 --> Jun 2021
- | Trial initiation date, Metastases: Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or Gemcitabine (clinicaltrials.gov) - Dec 26, 2018
P2, N=42, Not yet recruiting, Sponsor: HonorHealth Research Institute
Trial completion date: Sep 2019 --> Jun 2021 | Trial primary completion date: Sep 2019 --> Jun 2021 Initiation date: Nov 2018 --> Feb 2019
- || Opdivo (nivolumab) / BMS, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P1/2 trial: Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer (clinicaltrials.gov) - Dec 23, 2018
P1/2, N=40, Not yet recruiting, Sponsor: University of Michigan Cancer Center
- |||| Bavencio (avelumab) / EMD Serono, Herceptin (trastuzumab) / Roche
New P2 trial: Trial of mFOLFOX6 + Trastuzumab + Avelumab in Gastric and Esophageal Adenocarcinomas (clinicaltrials.gov) - Dec 21, 2018
P2, N=63, Not yet recruiting, Sponsor: Michael Sangmin Lee
- || Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial completion, Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Dec 20, 2018
P1, N=36, Completed, Sponsor: Oncolytics Biotech
Initiation date: Nov 2018 --> Feb 2019 Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Feb 2018
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Enrollment closed, Metastases: IriGen: Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 20, 2018
P2, N=47, Active, not recruiting, Sponsor: Centre Jean Perrin
Active, not recruiting --> Completed | Trial primary completion date: Oct 2018 --> Feb 2018 Recruiting --> Active, not recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Trial completion date, Mismatch repair, Metastases: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) (clinicaltrials.gov) - Dec 20, 2018
P3, N=308, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Active, not recruiting Trial completion date: Sep 2019 --> Feb 2021
- |||||| Modufolin (arfolitixorin) / Isofol Medical, Solasia
Enrollment open, Combination therapy, Metastases: AGENT: A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 19, 2018
P3, N=440, Recruiting, Sponsor: Isofol Medical AB
Trial completion date: Sep 2019 --> Feb 2021 Not yet recruiting --> Recruiting
- | New P2 trial, Metastases: FOLFIRINOX for 2nd-line Treatment of BTC (clinicaltrials.gov) - Dec 19, 2018
P2, N=49, Not yet recruiting, Sponsor: Dong-A University Hospital
- | Oncorine (recombinant human adenovirus type 5) / Mergen Ltd.
New P3 trial: HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B (clinicaltrials.gov) - Dec 19, 2018
P3, N=304, Recruiting, Sponsor: Sun Yat-sen University
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
New P2 trial, Metastases: Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer (clinicaltrials.gov) - Dec 19, 2018
P2, N=40, Not yet recruiting, Sponsor: University of Rochester
- | Xpovio (selinexor) / Karyopharm
Enrollment change, IO biomarker: NCI-2015-00693: Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination with Multiple Standard Chemotherapy or Immunotherapy Agents in Patients with Advanced Malignancies (clinicaltrials.gov) - Dec 17, 2018
P1, N=247, Recruiting, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting N=588 --> 247
- | Imfinzi (durvalumab) / AstraZeneca
New P2 trial: ARION: Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer (clinicaltrials.gov) - Dec 17, 2018
P2, N=120, Active, not recruiting, Sponsor: UNICANCER
- | methotrexate IV / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion: High-Dose Methotrexate and Leucovorin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (clinicaltrials.gov) - Dec 16, 2018
P2, N=36, Completed, Sponsor: Eastern Cooperative Oncology Group
N=588 --> 247 Active, not recruiting --> Completed
- | Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial, PD(L)-1 Biomarker, IO biomarker: Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma (clinicaltrials.gov) - Dec 16, 2018
P2, N=40, Not yet recruiting, Sponsor: University of Kansas Medical Center
- | NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial (clinicaltrials.gov) - Dec 14, 2018
P2/3, N=79, Completed, Sponsor: Sun Yat-sen University
Active, not recruiting --> Completed Recruiting --> Completed | N=262 --> 79 | Trial completion date: Jan 2016 --> Sep 2018 | Trial primary completion date: Sep 2015 --> Sep 2018
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Enrollment open, Combination therapy, Metastases: CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 14, 2018
P2, N=33, Recruiting, Sponsor: Jeffrey Hardacre
Recruiting --> Completed | N=262 --> 79 | Trial completion date: Jan 2016 --> Sep 2018 | Trial primary completion date: Sep 2015 --> Sep 2018 Not yet recruiting --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 13, 2018
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Mar 2022 --> Oct 2022
- Kinaction (masitinib) / AB Science
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 13, 2018
P3, N=186, Terminated, Sponsor: AB Science
Trial primary completion date: Mar 2022 --> Oct 2022 Trial completion date: Jun 2018 --> Dec 2017 | Trial primary completion date: Jun 2018 --> Dec 2017
- | Clinical, Review, Journal: The Adjuvant Treatment of Stage III Colon Cancer: Might Less Be More? (Pubmed Central) - Dec 13, 2018
Oxaliplatin-based chemotherapy (FOLFOX [folinic acid, fluorouracil, oxaliplatin] or XELOX [oxaliplatin, capecitabine; also called CAPOX]) for 6 months is the current standard for adjuvant therapy of stage III colon cancer patients with good performance status...The goal of the International Duration Evaluation of Adjuvant (IDEA) study was to evaluate the noninferiority of 3-month compared with 6-month adjuvant oxaliplatin-based treatment in stage III colon cancer using a prospectively designed pooled analysis of 6 concurrently conducted phase III randomized trials. Herein, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors.
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial completion date, Trial initiation date, Trial primary completion date, Combination therapy: NEO-Nal- IRI: A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma (clinicaltrials.gov) - Dec 12, 2018
P2, N=28, Recruiting, Sponsor: University of Florida
Herein, we review the findings of the IDEA study and discuss the optimal duration of oxaliplatin-based adjuvant chemotherapy using patient-based risk factors. Trial completion date: Sep 2020 --> Dec 2021 | Initiation date: Aug 2018 --> Jan 2019 | Trial primary completion date: Sep 2020 --> Sep 2021
- | New P2 trial: INTENSE: Irinotecan-based Triplet (FOLFOXIRI) as Perioperative Treatment in Resectable Gastric and Gastroesophageal Junction Adenocarcinoma. (clinicaltrials.gov) - Dec 12, 2018
P2, N=60, Not yet recruiting, Sponsor: Lund University Hospital
- | New P3 trial: HAIC Versus Systemic Chemotherapy for Unresectable ICC (clinicaltrials.gov) - Dec 11, 2018
P3, N=188, Recruiting, Sponsor: Shi Ming
- || navicixizumab (OMP-305B83) / Feng Biosci
Enrollment closed, Metastases: A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 7, 2018
P1b, N=30, Active, not recruiting, Sponsor: OncoMed Pharmaceuticals, Inc.
Trial completion date: Sep 2020 --> Dec 2021 | Initiation date: Aug 2018 --> Jan 2019 | Trial primary completion date: Sep 2020 --> Sep 2021 Recruiting --> Active, not recruiting
- | Kinaction (masitinib) / AB Science
Enrollment change, Trial termination, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 5, 2018
P3, N=186, Terminated, Sponsor: AB Science
Recruiting --> Active, not recruiting N=550 --> 186 | Recruiting --> Terminated; Sponsor decision based on portfolio prioritization
- ||||| Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial: LyRICX: Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer (clinicaltrials.gov) - Dec 5, 2018
P2, N=310, Not yet recruiting, Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer (clinicaltrials.gov) - Dec 4, 2018
P3, N=225, Completed, Sponsor: National Cancer Institute (NCI)
N=550 --> 186 | Recruiting --> Terminated; Sponsor decision based on portfolio prioritization Terminated --> Completed | N=3000 --> 225 | Trial primary completion date: Jan 2100 --> Nov 2016
- || Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: FABLOx: Study of 5-fluorouracil (5-FU), Nab (clinicaltrials.gov) - Dec 3, 2018
P1/2, N=12, Completed, Sponsor: Celgene
Terminated --> Completed | N=3000 --> 225 | Trial primary completion date: Jan 2100 --> Nov 2016 Active, not recruiting --> Completed
- ||||| Kinaction (masitinib) / AB Science
Enrollment closed, Combination therapy, Metastases: Masitinib in Combination With FOLFIRI in Third or Fourth Line of Treatment of Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 3, 2018
P2/3, N=219, Active, not recruiting, Sponsor: AB Science
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- || CYAD-101 / Celyad Oncology
Enrollment open, Trial completion date, Trial primary completion date, CAR T-Cell Therapy, Metastases: alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells (clinicaltrials.gov) - Dec 3, 2018
P1, N=36, Recruiting, Sponsor: Celyad (formerly named Cardio3 BioSciences)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting | Trial completion date: Oct 2034 --> Oct 2033 | Trial primary completion date: Oct 2021 --> Nov 2020
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment closed, Trial completion date, Metastases: MM-398-07-02-03: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Nov 30, 2018
P1/2, N=56, Active, not recruiting, Sponsor: Ipsen
Not yet recruiting --> Recruiting | Trial completion date: Oct 2034 --> Oct 2033 | Trial primary completion date: Oct 2021 --> Nov 2020 Recruiting --> Active, not recruiting | Trial completion date: Oct 2019 --> Feb 2020
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
New P1 trial: A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma (clinicaltrials.gov) - Nov 29, 2018
P1, N=24, Not yet recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Trial completion date, Trial primary completion date: PePiTA: Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer (clinicaltrials.gov) - Nov 29, 2018
P=N/A, N=235, Active, not recruiting, Sponsor: Jules Bordet Institute
Recruiting --> Active, not recruiting | Trial completion date: Oct 2019 --> Feb 2020 Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2022 | Trial primary completion date: Dec 2017 --> Dec 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Nov 29, 2018
P2, N=50, Recruiting, Sponsor: howard safran
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2022 | Trial primary completion date: Dec 2017 --> Dec 2022 Trial completion date: Dec 2018 --> Dec 2019 | Trial primary completion date: Sep 2018 --> Sep 2019